A B S T R A C T
Complement immunobiology, and with it complement analysis, has undergone a renaissance in the past decade. Classically, complement analysis was limited number of testing C3, C4 in a routine laboratory with the possible addition of CH50 with all other analysis being performed at only few highly esoteric laboratories. This diagnostics expanding beyond specialized laboratories is the result of the growing recognition of the role played by complement dysfunction in many more diseases and disorders and the concomitant increase in interest in complement targeting therapeutics. In response, laboratories specializing in complement analysis have joined with the International Complement Society and the IUIS to coordinate e orts to standardize and improve ff complement testing, ongoing e orts that have already borne fruit. A recognition of the power of complement ff analysis has brought forward new testing but also realization of the importance of post-draw specimen handling to limit activation, as well as the sometimes large di erence between testing laboratory results. The ex vivo ff increased usefulness of complement analysis and e orts to standardize and expand it means the future is strong ff for complement analysis.
Changing landscape of complement testing: growing clinical importance
The complement system is a set of proteins involved in the interconnected cascade of pro-enzymes, regulatory proteins, recognition molecules, signing molecules and receptors. Complement was rst defi scribed in the late 1800 s, but the list of components continues to grow. ' The system is composed of more than 30 proteins and has long been known for its ability to kill invading microbes at rst exposure. As fi critical part of the innate immune system, di erentiation of self from ff non-self involves important tagging of self and control of complement on host surfaces ( ; ). Zipfel and Skerka, 2009 Ricklin et al., 2010 For decades the primary, and nearly exclusive, use of complement testing was to test for primary immunode ciencies or to de ne disease fi fi activity in systemic autoimmune diseases, focusing on a limited number of rheumatological or nephrology disorders ( ; Ricklin et al., 2010 Skattum et al., 2011 de Cordoba et al., 2012 Holers, 2014 ; ) . Only a small number of tests were used, mainly to assess total complement function, C3 and C4. While speci city was important, not a great deal of fi sensitivity was needed. With the abundance of components of complement in circulation, C3 being the highest at 1 to 1.5 mg/mL, the presence or absence of the proteins in the cascade could be measured by relatively simple methods ( ). However, the Morley and Walport, 2000 fi fi eld has changed dramatically due to signi cant developments in complement science. First, there has been a notable increase in the number of diseases and disorders recognized to be closely associated (driven by) complement (Table 1) ( Thurman and Holers, 2006; Hajishengallis et al., 2017) . The diseases now recognized to connect to complement are anatomically diverse, ranging from the kidney to the eye, from the rare atypical hemolytic uremic syndrome to common disorders like age-related macular degeneration. The pathophysiology of these disorders is often driven by the strong pro-in ammatory fl properties of complement which can a ect so many properties of ff biology in so many tissues and organ systems. That can, in turn, be traced back to the original task of complement which is to ght infi fectious invaders. As a rst line of defense, complement has a powerful fi potential to tag and even destroy invading microbes while activating the larger immune system to clear the potential damage (Walport, 2001 Skattum et al., 2011 . These are functions that can be very damaging if turned on the host tissues. Many of the complement-connected disorders are, unsurprisingly, associated with an inappropriate over-activation of complement or with a failure to control complement. Some of these activations or losses of control, such as seen for mutations in complement Factor H, can be far more subtle than the yes or no , 2015 Medjeral-Thomas and Pickering, 2016 Parente et al., 2017 . The mutations can involve subtle changes in function, changes limited to circulation or to those on a cell surface. Detecting these more nuanced alterations in complement requires a more nuanced testing in the diagnostic laboratory.
The second event that has changed the landscape for complement analysis was the advent of therapeutics that directly target complement ( ). Starting in 2007, the rst complement-speci c Ricklin et al., 2017 fi fi therapeutics entered the market. With this there is a need to not only diagnose the disease but also follow the treatment. This changed the analysis from needing to show only if a complement component were de cient to needing to know if the function was suppressed to 10% of fi normal, for example ( ). This led to the developProhaszka et al., 2016 ment of new assays and to the appreciation of new values in existing, but formerly rare or esoteric, tests. In addition, it has helped topropel e orts to improve the standardization between laboratories and the ff quality of complement testing overall. Consequently, existing laboratories specializing in complement have improved, plus there is now an increase in complement testing in the more general, large laboratories. This produces more pressure for the tests to be robust and reliable ( ). Mollnes et al., 2007 2. Importance of complement functional testing Some of the earliest testing performed for complement was functional testing, and the utility and interest in the analysis of function of complement remains ( ). In one functional assay it Prohaszka et al., 2016 is possible to test for the presence and functionality of all the components of an activation pathway and the terminal pathway at once ( A). This ability to broadly test for complement function of a Fig. 1 number of components of the cascade has led to an assay being referred to as a Total Complement Activity test, but it generally references the " " classical pathway functional assays. Functional complement testing proved very useful in screening for an immunode ciency or complefi ment activation with consumption. For immunode ciency testing the fi more common classical pathway activity test (also called 'CH50') is combined with an alternative pathway activity (or AH50) assay to quickly determine where in the cascade system a de ciency lies; clasfi sical, alternative, or the shared terminal ( A). This dramatically Fig. 1 reduces the work required to determine the speci c component defi fi ciency. On the activation side, if a patient has an ongoing complement consumption depletion of available complement is re ected in a defl creased measurable function. This has proved useful for testing for flares in autoimmune disease ( ; ). Spronk et al., 1995 Le er et al., 2014 ffl This utility has been the prime driver in the development of the now multiple methods for testing complement function. The types of complement functional analysis largely fall into three categories, each with their own bene ts and disadvantages. What these tests share is a need fi to rst activate the speci fi fi c pathway of interest, then measure the formation of the terminal complement complex in solution or by functional outcome. De ned bu er components, or the addition of infi ff hibitory antibodies, are used to keep the other activation pathways in check. For example, the inclusion of calcium chelators (e.g. EDTA) inhibits the classical pathway through destablization of the C1 complex ( ; ). The most historic Eagle and Brewer, 1929 Kabat and Mayer, 1961 form of complement function testing is what is referred to as a hemolytic test. In this method, an animal red blood cell (RBC), generally a sheep RBC, is coated with antibodies (hemolysin) making it an optimal target for classical pathway recognition. This recognition leads to activation which then results in the formation of the membrane attack complex (MAC) on the surface of the red blood cell. The MAC leads to lysis of the RBC and release into solution of the hemoglobin (Kabat and Mayer, 1961) . The hemoglobin is easily quantitated by spectrophotometry which can then be related back to the percentage of RBC s ' that were lysed and the functionality of complement to do the lysing. As this is a sequential cascade involving the whole pathway, the relation between the concentration of serum and the amount of lysis is not linear. It is instead more sigmoidal, following the von Krug equations ( ). Therefore, the traditional method for running a Jackson et al., 1970 hemolytic assay was to run a ve-point serial dilution of serum or fi plasma, then use the three points that form the most linear portion of the curve that covers the mid-point of lysis, where half the RBC are lysed. From there the dilution that would lead to lysis of exactly 50% of the RBC is calculated, and the result reported as the reciprocal of that dilution ( ). Some of the newer methods instead Kabat and Mayer, 1961 will report results as percentage of a normal or standard value. For the hemolytic method it is the relation to the report of the 50% lysis point that gives the test the abbreviated CH50 for the classical pathway assay. A similar assay, the AH50, can be performed where the target RBC is of rabbit, guinea pig or chicken origin as, unlike sheep RBCs, these are activating surfaces for the alternative pathway. Care should be taken if using these assays to screen for properdin de ciency as they all do not fi perform equally ( ). For the alternative Kirsch nk and Mollnes, 2003 fi pathway assays, classical pathway is kept inactive by chelating calcium (e.g. by EGTA) necessary to maintain the C1 complex. These hemolytic assays have the advantage of having the greatest sensitivity at the low end of function. Since they are also so complex, however, a specialized laboratory is required. Because they rely on live cells, there is the potential for variability in supply that needs to be very carefully controlled.
The most common method nowadays used in US clinical laboratories for measuring total complement is based on lysis of a liposome. In this assay a synthetic liposome stands in for the RBC of the hemolytic assay. The liposome is loaded with an enzyme, such as glucose-6-phosphate, that is easily measured on a common clinical laboratory chemistry analyzer ( ). As for the CH50, the liFrazer-Abel et al., 2016 posome is coated with antibody to activate the classical pathway, one concentration of serum or plasma is then used in the reaction mixture and the amount of enzyme release is measured. This assay is very well suited to a large hospital-type laboratory, as it is automated with high throughput, thus fairly inexpensive to run. This testing has proven very useful when a fast yes or no answer is needed, but there is evidence that this type of assay is not su ciently sensitive for monitoring nuanced ffi changes at either end of the functional spectrum ( ). Gatault et al., 2015 It is important to keep this in mind when measuring low levels of A more recent addition is the ELISA style complement function assays. There are currently at least three commercially available forms of the classical pathway function assay that have regulatory approval in the US (Quidel & DiaSorin) or in the EU (Wieslab, Eurodiagnostica). These assays have rapidly gained popularity and are now utilized by an increasing number of laboratories. As an ELISA style assay, it is well suited to being run in an immunology laboratory without access to high quality RBC and without requiring the same level of expertise in complement analysis. While the three assays di er they all utilize antiff bodies on the plate, or complexes in solution, to activate the C1 complex and then measure the production of the membrane attack complex, a measure of the level of complement activation that occurred. Wieslab also has kits for the alternative and lectin pathway function which a ord a more complete investigation of complement ff function ( ). Like the liposomal assay, these are Mollnes et al., 2007 largely regulatory-approved assays for patient diagnostics, and therefore they have the bene t of strong supply chain control, low lot-to-lot fi variability and higher throughput than the traditional hemolytic assay. Depending on the assay and the way the data is calculated, the sensitivity can be better than the liposomal assay at the lower end of function. This makes these assays generally well suited to follow the therapeutic blockade of complement, perhaps trading some low level detection for more consistent quantitation and reproducibility than the hemolytic assay generally.
In addition to the functional assays that evaluate the function of an entire pathway, there are also specialized tests to assay the functionality of the individual components. These too can take a number of forms, but are almost exclusively developed in individual laboratories. As such, comparison between laboratories can be quite di cult and ffi availability of individual tests may be limited. Even with these issues there can be bene t to seeking out such testing because for a number of fi components of complement, measuring the level will not be su cient ffi to determine if a de ciency or dysfunction is present. Speci cally, for fi fi the C2 type II de ciency, a dysfunctional protein requires to measure fi the function to diagnosis. Similarly, C8, as it is a multi-subunit protein, can have low normal levels but lack functionality, if one subunit is de cient.
fi The functional assays are also now commonly used to analyze complement blockade by therapeutics. However, there is growing interest in measuring the split products (C4d, C3a, C3d or Bb) and complexes (sC5b-9) to better de ne the level of complement activation or fi inhibition. These assays have the potential to add more detail and sensitivity to the functional assays. Measurements of the soluble terminal pathway activation complex sC5b-9 (sometimes referred to as soluble membrane attack complex, sMAC) can assess potential response level to complement blockade as well as monitor the completeness of that blockade. If, for example, the complement system and C5 is fully blocked the ability to form the sC5b-9 complex should also be inhibited. There are con icting reports regarding the utility of this testing fl ( ), questioning the value of sC5b-9 to precisely Wehling et al., 2017 re ect complement inhibition, e.g. by eculizumab ( ). fl Noris et al., 2014 In addition, there are some documented issues related to the consistency of results between laboratories ( ). Measurements Bu et al., 2015 of the inhibition of the convertases has been found by some laboratories to be a promising method for stratifying patients. Convertases are the multi-component enzymatic units that cleave C3 (C3bBb, C4bC2a) and C5 (C3bBbC3b, C3bC2aC3b), respectively. This testing is currently available in a limited number of laboratories ( ).
Blom et al., 2014
The value of measuring activation products can be twofold. First, they pinpoint one pathway or component. This has the potential to test the level of control of an individual component, in addition to being able to di erentially specify which pathway is activated or inhibited ff ( ). As well as di erentiating the point of actiFrazer-Abel et al., 2016 ff vation or control, measurement of the split products or complexes can be more sensitive than the measurement of total function (Frazer-Abel et al., 2016, unpublished data) . The functional assays interrogate the whole pathway, so it is not possible to determine the speci c ratefi limiting component nor the step in the pathway. Combining complement activation markers can reveal the point of inhibition and if that inhibition a ects the upstream portion of the cascade or if the underff lying complement activation is still in process ( B). Fig. 1 
Complication of specimen handling
Historically one of the bigger impediments to the adoption of complement testing by physicians has been the potential issues around ex vivo activation of complement and the resulting uncertainty of the results. It has long been known that if serum and plasma for complement analysis are not handled correctly, the results can di er greatly ff from the values for the patient at the time of draw. Work from Mollnes and colleagues demonstrated some pretty remarkable increases in the levels of activation fragments after storage a 4°C ( ). Mollnes et al., 1988 In work by Yang et al., they concluded that if EDTA was included in the sample at a concentration of > 10 mM the levels of C3a, C4d, C5a and sC5b-9 were consistent for four hours at room temperature and 24 h at 4°C ( Yang et al., 2015) . An important note for this testing was that it was performed on collections from normal individuals. A lot of testing for diagnostics or clinical trials will be performed on specimens from individuals with ongoing complement activation, due to the presence of complement activators (immune complexes, cryoglobuline, paraproteins, septic samples, etc.), or dysregulation in the sample. If there is strong baseline activation there is the possibility of more in vivo ex vivo activation. For one patient, the level of C4a measured increased after one hour at room temperature and doubled at four hours. This variable has been found among patients, with some results remaining consistent over time. (unpublished data, Frazer-Abel) . If you look at the specimen production instructions for a complement specialty laboratory or the instructions for sample preparation included in a complement kit inserts, the recommendations will be to get the specimen processed and frozen at 80 °C within an hour, or at most two hours. Even then there − is data that storage at 80 °C is not su cient to stabilize complement − ffi for extended storage over six to 10 years ( ). Morgan et al., 2017 In addition to sample handling concerns, there are also considerations around the subject. One of these factors can be the level of stress in the subject. Work from ) demonstrated marked Burns et al. (2008 increases in complement activation fragments in response to a psychological stress ( ). Normal subjects were giving a Burns et al., 2008 paced auditor serial addition task (PASAT) which has been shown to cause stress responses in individuals. For this testing an additional burst of noise was included for each incorrect answer. C3a and Bb levels increased markedly at the time the task was performed while C5a increased 30 min after the test. Of potential importance for this study, all testing was performed in the afternoon. This is important because there is some data on the e ect of the circadian rhythm and sleep on comff plement levels. Work from Reis et al. in 2011 looked at the levels of C3 and C4 as well as the split product C3a over the circadian cycle (Reis et al., 2011) . C3 and C4 levels decreased during the night, but the change was independent of the sleep-wake cycle. C3a, by contrast, increased at night but that increase was lost if the subject did not sleep. While there was some controversy around the circadian cycle e ect on ff complement, there is clearly enough data to consider it a possibility. These factors point to the value of obtaining baselines levels on a patient or subject, if possible. While there are reference ranges for the complement components, there are also individual di erences. ff
Progress and e orts to standardize complement analysis ff
With this increased attention and the new demands on complement testing, it was clear to the experts that there was a need to improve the consistency and quality of the testing. From this recognized need, a standardization and quality committee was developed out of the XXII , 2016) . Since that time seven rounds of external quality assessment, now covering 18 parameters (function, proteins, activation products and autoantibodies), have been completed. These e orts have shown the ff need for such standards and resulted in improvements in the consistency of testing across participating institutions, while extending the global reach of the e orts. ff Now that these e orts are well underway and bearing fruit, e orts ff ff have turned to creating a recognized standard with de ned amounts of fi the individual components. These e orts are necessary because curff rently there is only one WHO standard that includes a limited number of complement analyses; it is now over 40 years old and increasingly di cult to obtain (1 ffi st International Reference Preparation, 1980, Code W1032; Document 80.1281; Human serum complement components C1q, C4, C5, factor B, and whole functional complement CH50).
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